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ADHERENCE THROUGH THE PROCESS OF AUDIT, LED BY JUNIOR DOC-
TORS
Gerard Walls *, David Curry, Hugh O'Kane. Regional Urology Unit, Belfast City
Hospital, Northern Ireland, UK.
Introduction: The authors intended to establish adherence to guidelines
regarding time to administration of intravesical chemotherapy post-
TURBT, in the Regional Urology Unit. EORTC recommends Mitomycin C
(MMC) instillation within 6 hours in eligible patients - this reduces
recurrence rates by 39%.
Methods: Prospective audit of time to administration in all eligible pa-
tients during a 3 month period. Results were discussed at departmental
level with a three tiered approach to improvement. Primarily, initiation of
in-theatre instillation (Mostaﬁd et al). Second, a training programme for
ward staff in handling cytotoxic agents. Finally, awareness of the problem
was raised to trainee urologists at the Regional Audit Meeting. A repeat
three month audit series was performed six months later. The latter two
processes had been implemented with plans for in-theatre administration
on-going.
Results: Initially, in 19 patients (40 eligible) the mean time to MMC
administration was 18.3hrs (2.3-28.2hrs). 15.7% patients received MMC
<6hrs. In the second series of 9 patients (13 eligible), the meantime to
MMC administration was 5.2hrs (1-17.25hrs), and 88.9% received MMC
<6hrs (none after 24hrs).
Conclusions: Improvement in MMC administration practice is seen
following simple interventions led by junior doctors. Through on-going
training, adjustment of systems and audit, we hope further improvements
can be seen.
0379: AN AUDIT OF UPPER RENAL TRACT UROTHELIAL BIOSPY: OUR
INITIAL EXPERIENCE OF BIGOPSY FORCEPS
Sotonye Tolofari *, Basharat Hussain, Wai-Man Chow. Pennine Acute
Hospitals NHS Trust, Manchester, UK.
Introduction: Biopsy is the gold standard for diagnosis of upper renal tract
malignancy. It's always an urologist's challenge to achieve a representative
sample for accurate diagnosis. Recent evidence suggests 3mm is the
minimal biopsy size required for adequate histopathological diagnosis. We
present an audit of our experiences with different biopsy devices.
Methods: 45 patients underwent ureteroscopic/ureterorenoscopic biopsy
of urothelial lesions. All biopsies were sent for analysis by a histopathol-
ogist with an expertise in urological pathology.
Results: 33 patients underwent urothelial biopsies using the following
devices; Piranha(29), reusable forceps(3) and Dormia basket(1). There
were 31 ureteric lesions and two pelvicalyceal lesions. Specimen sizes
ranged from <1mm (5), 1mm (14), 2mm (8) and 3mm (2). 8 patients
required a re-biopsy. Further immunohistochemical analysis (4) and re-
petitive reviews (4) were required for diagnostic conﬁrmation. 12 patients,
underwent biopsies of ureteric lesions (10) and pelvicalyceal lesions (2)
using BIGopsy forceps. All specimens were measured >3mm, ﬁrst time.
Unanimous, unequivocal histopathological diagnoses were achieved.
Conclusions: Few biopsy devices provide satisfactory, representative and
consistent samples for diagnosis. We experienced an unpredictable
outcome with a 25% re-biopsy rate with various devices, however with
BIGopsy forceps accurate histopathological diagnoses were achieved with
a signiﬁcant impact on the timely treatment for urothelial malignancies.
0401: HOW CLINICAL AUDIT HAS LED TO REDUCED RATES OF POST
TRUS BIOPSY SEPSIS IN OUR TRUST
Nicholas Gill *, Michael Onyema, Anne Dyas, Vincent Koo, Paul Rajjayabun.
Alexandra Hospital, Redditch, UK.
Introduction: We recently reported the ﬁndings of a regional audit which
identiﬁed rates of sepsis increasing to 1.8% following transrectal ultra-
sound guided prostate biopsies (TRUS). Following this audit I.V. Genta-
micin 160mg was introduced as additional prophylaxis for patients
undergoing TRUS biopsy. Our aim was to assess the impact of adding
Gentamicin to the TRUS antibiotic prophylaxis bundle since implementa-
tion in August 2013.
Methods: Analysis of all patients who underwent TRUS biopsy across our Trust
between August-December 2013 with minimum 1-month follow up. Our ﬁnd-
ings were compared against our previous audit data and published literature.Results: Therewere 246 TRUS biopsy procedures carried out across the Trust
following the introduction of our new antibiotic prophylaxis regime. Median
age of the population examined was 67 years (range 42-84). Only 1 patient
was admitted to Secondary care with signiﬁcant sepsis (0.4%), 3 patients had
positive urine cultures performed inPrimarycare but didnot require hospital
admission (1.2%). There were no ITU admissions or mortalities.
Conclusion: We conclude that the addition of I.V. Gentamicin has
dramatically reduced the incidence of signiﬁcant sepsis post-TRUS biopsy.
This is an example of howwe have utilised audit tomodify clinical practice
for the beneﬁt of our patients.
0403: PROGNOSIS FOLLOWING PERCUTANEOUS NEPHROSTOMY INSER-
TION FOR MALIGNANT OBSTRUCTIVE UROPATHY: ONE CENTRE'S EXPE-
RIENCE
Nicholas Gill *, Kevin Williams, Phil Holland, Chris Phillips, Fabio Conti,
K. Wong, L. Delaney, L. Moore, Paul Rajjayabun. Alexandra Hospital,
Redditch, UK.
Introduction: Traditionally long-term survival post-nephrostomy inser-
tion for obstruction secondary to malignant uropathy has been variable,
however, it is often seen as a manifestation of disease progression. Our aim
was to assess patterns of nephrostomy insertion for patients presenting
with malignant ureteric obstruction in the modern era.
Methods: We analysed the nephrostomy service provided by our depart-
ment from January 2011 to June 2013. We focused on the indication of
malignant obstructive uropathy with a minimum of 5 months follow up.
Each nephrostomy insertion was considered a separate event.
Results: A total of 138 nephrostomy procedureswere performed for ureteric
obstruction secondary to pelvic or abdominal malignancy (n¼138, 68%).
There were 46 (33%) female and 92 (67%) male patients. Median patient age
was 72.2 (range 42-91) years. Obstruction secondary to prostate cancer (34%)
and bladder cancer (34%)were themost frequent indication for intervention.
Median survival post-insertion was 73 (range 2-593) days with only 30% of
this patient group demonstrating long-term survival. A signiﬁcant group of
patients failed to survive for >30 days post-procedure (n¼19, 12%).
Conclusions: Nephrostomy insertion for malignant ureteric obstruction is
a hallmark of disease progression. Patients who undergo this invasive
procedure often have poor survival characteristics. Each should be coun-
selled carefully before undertaking nephrostomy insertion.
0519: A RETROSPECTIVE AUDIT OF POST TRUSS GUIDED PROSTATE BI-
OPSY SEPSIS IN A DISTRICT GENERAL HOSPITAL e HOW ADEQUATE IS
ANTIBIOTIC PROPHYLAXIS IN THE FACE OF RISING RESISTANCE?
Kathleen Sweeney, Fungai Dengu *, Ismail El-Mokadem, Steve Leung.
Department of Urology, Victoria Hospital Kirkcaldy, Kirkcaldy, Fife, UK.
Introduction: Recent evidence suggests a rising incidence of serious
infective complications following TRUSS biopsy associated with signiﬁcant
morbidity and mortality due to ﬂuoroquinolone resistance. This audit aims
to determine the incidence of post biopsy sepsis in our hospital.
Methods: We retrospectively reviewed data from a prospectively main-
tained database of patients who underwent TRUSS biopsy over a 12-month
period at our District General Hospital. All patients received the standard
protocol of Ciproﬂoxacin and Metronidazole. We identiﬁed patients pre-
senting with symptoms suggestive of sepsis up to 30 days post TRUSS
biopsy. We reviewed their case notes to identify the rates of bacteuria,
bacteraemia and hospital admissions.
Results: 319 patients were biopsied and 22 (6.9%) presented with symp-
toms suggestive of infective complications. 10 (3.1%) had organisms
cultured from urine specimens and none had a bacteraemia. Only 2 (0.6%)
were admitted to hospital with clinically signiﬁcant urosepsis, both
culturing ﬂuoroquinolone resistant E. Coli.
Conclusions: Although ﬂuoroquinolone resistance may be increasing and
urosepsis is a life-threatening complication associated with resistance; our
results show it is a rare complication in our unit. Therefore no change in
antibiotic prophylaxis is warranted at present. However re-auditing is
essential to identifying the reported emergence of clinically signiﬁcant
resistance.
0558: THE INCIDENCE OF UTI FOLLOWING FLEXIBLE CYSTOSCOPY:
SHOULD WE CHANGE OUR ANTIBIOTIC PRACTICE?
Luke McGuinness *, Sophie Christopher, Ciaran Lynch. Royal Liverpool and
Broadgreen University Hospitals, Liverpool, UK.
Abstracts / International Journal of Surgery 12 (2014) S13eS117 S105Introduction: Flexible cystoscopy (FC) is a common urology procedure;
over 220,000 are performed in UK annually. Urinary tract infection (UTI) is
a potential complication with rates varying from 0.8-10%; most requiring
antibiotic treatment in primary care. There is on-going debate regarding
antibiotic prophylaxis for FC. Our aim was to evaluate the incidence of UTI
following FC in our institution ascertaining whether prophylaxis is indi-
cated. Identify the antibiotic proﬁle of causative organisms to guide
treatment of post-FC UTIs.
Methods: We retrospectively analysed 288 patients who underwent FC
over 3months. Patients were cross-matched with our microbiology results
reporting system (Sunquest-Ice€a) to identify those who had a urine sample
sent for analysis within 30 days of their procedure.
Results: Of the 288 FCs performed 37 patients (12.8%) had a urine sample
sent for microbiology analysis. Twenty-ﬁve were from primary care and 15
from hospital with the median time from FC of 15 days. Ten samples
showed signiﬁcant bacterial growth with E. coli predominating. Most were
sensitive to cefalexin (75%), nitrofurantoin (100%) or trimethoprim (67%).
No organisms had extended antibiotic resistance.
Conclusions: Our incidence of post-FC UTI is 3.47% suggesting prophylaxis
is unwarranted. No extended antibiotic resistance was exhibited therefore
no changes to antibiotic recommendations are required.
0580: RISKS AND ASSOCIATIONS OF FISH-OIL PRODUCTS WITH PROS-
TATE CANCER: A STUDY OF 492,283 PARTICIPANTS
Catherine Lovegrove *, Kamran Ahmed, Hamid Abboudi, Saied Froghi,
Rick Popert, M Shamim Khan, Prokar Dasgupta. King's College London,
London, UK.
Introduction: The role of ﬁsh-oils in inﬂammation entails potential
carcinogenesis inhibition and improved cancer symptoms. This system-
atic-analysis aims to review evidence for the role of dietary-ﬁsh and ﬁsh-
oil intake in prostate-cancer (PC) risk, aggression and mortality.
Methods: A systematic-review of literature on PC-risk, aggression and
mortality associated with dietary-ﬁsh and ﬁsh-oil intake was conducted
through PubMed, MEDLINE and Embase. Outcome-measures (PC-risk,
aggression and mortality) were extracted for analysis.
Results: 492,283 (36-studies) participants were investigated. These
revealed various relationships regarding PC-risk (n¼30), aggression (n¼7)
and mortality (n¼3). Nine studies considering PC-risk demonstrated sig-
niﬁcant inverse trends with ﬁsh or ﬁsh-oil intake. One found a dose-
response relationship whereas increased long-chain-polyunsaturated-
fatty-acids heightened PC-risk (p¼0.014). Three studies identiﬁed a
signiﬁcantly reduced risk of aggressive disease. This applied to greatest
intake of total ﬁsh (OR 0.56 (95% CI 0.37e0.86)), dark-ﬁsh, shellﬁsh-meat
(p<0.0001), EPA (p¼0.03) and DHA (p¼0.04). Three studies investigating
ﬁsh-consumption and PC-mortality identiﬁed signiﬁcant risk reduction.
Multivariate-OR(95% CI); 0.9(0.6-1.7), 0.12(0.05-0.32) and 0.52(0.30-0.91)
at greatest measured ﬁsh-intakes.
Conclusions: Fish and ﬁsh-oil may be important in reducing PC-
incidence, aggression and mortality. Results suggest that ﬁsh type and
ﬁsh-oil ratios are signiﬁcant considerations. Findings demonstrate po-
tential for incorporation into campaigns for primary and secondary
prevention.
0604: AN AUDIT OF THE COMPLIANCE OF HARROGATE DISTRICT HOSPI-
TAL'S CURRENT POST VASECTOMY CLEARANCE SERVICE
Clare Jelley *, Annemarie Davies. Harrogate and District NHS Foundation
Trust, North Yorkshire, UK.
Introduction: A vasectomy is a common procedure and our current
guidelines taken from BAS 2002 require 2 negative sperm samples for
clearance, at 16 and 18 weeks post-operatively. Multiple posted samples
were reported as “scanty”, resulting in further samples needed for clear-
ance. We aim to quantify this enabling us to implement change to improve
efﬁciency and reduce laboratory workload.
Methods: All of the patients who underwent a vasectomy from April 2012
toMarch 2013 were included. We analysed the time of the ﬁrst and second
sperm samples, the number of samples provided per patient and time to
clearance.
Results: 101 patients had a vasectomy and 6 were excluded. Of the 95 pa-
tients 34% gave 1 or no samples andonly 24%were cleared by20weeks. 25%
had 2 consecutive scanty results and only 8% gave a fresh sperm sample.Conclusions: A high proportion of patients are not sending any specimens,
while those that do often have to send multiple specimens due to scanty
results. We propose a simpler system to improve compliance and shorten
the time to clearance: 1 posted sample at 12 weeks followed by a fresh
sample if positive, in line with the EAU Guidelines 2012.
0641: READMISSION AND COMPLICATIONS FOLLOWING TRANSRECTAL
ULTRASOUND GUIDED PROSTATE BIOPSY
Luke McGuinness *, Manal Kumar. Wirral University Teaching Hospitals,
Merseyside, UK.
Introduction: Prostate cancer is the most commonly diagnosed cancer in
men in the UK. Transrectal ultrasound guided prostate biopsy (TRUSGPb)
forms the mainstay of diagnosis. Although considered low-risk serious
complications of bleeding and infection can result in hospitalisation and
mortality has been recorded. We evaluated our TRUSGPb over a 2yr period
and those admitted to hospital within 30 days with a biopsy related
complication.
Methods: A total of 810 patients underwent TRUSGPb in a two-year
period. Clinical coding computer systems identiﬁed those patients
admitted within 30 days. Clinical notes were used to ascertain reason for
admission and any biopsy related morbidity.
Results: Of the 810 patients undergoing biopsy 44 (5.4%) were admitted
within 30 days. Thirty (3.7%) were admitted with a TRUSGPb related
morbidity. The average time from biopsy to admission was 6 days and the
average length of stay was 3 days. Nine (1.1%) were admitted with infec-
tion, eight (1.0%) with urinary retention, seven (0.86%) with haematuria,
four (0.49%) with rectal bleeding and 2 (0.25%) with blocked urethral
catheter.
Conclusions: Our incidence of TRUSGPb related complications requiring
hospitalisation is 3.7% with infection and bleeding predominating. No mor-
tality was recorded indicating TRUSGPb continues to be a safe procedure.
0748: HOW SAFE IS IT NOT TO FOLLOW UP BOSNIAK 2 CYSTS?
Tsong Kwong *, Dev Gulur, Margerat Lyttle, Suzanne Amin,
Shankar Chandrasekhran, Andrew Baird, Mahmoud Elfar. Aintree
University Hospital, Liverpool, UK.
Introduction: Bosniak 2 renal cysts have been a subject of much debate
regarding follow up because of their malignant potential. There is a paucity
of published data on long term follow up and if they need it.
Methods: We reviewed the details of 56 patients who were prospectively
followed up for incidentally detected Bosniak type 2 cysts since 2007. Of the
56 patients 34 patients were included in the analysis. The others were lost to
follow up or died before 5 years. All the patients had an initial CT followed by
an annual USS. Mean agewas 69 years.19 weremale and 15 female patients.
Results: After a mean follow up was 5 years, the cysts in all the patients
have remained stable with no change in Bosniak classiﬁcation. There was a
slight increase in the cyst dimensions in 4 and decrease in 2 patients. All
the patients have now been discharged.
Conclusions: Our study has shown that all Bosniak 2 cysts have remained
unchanged over 5 years suggesting that they do not necessarily need
follow up provided a baseline pre and post-contrast CT has been per-
formed to accurately characterize them.
0776: EARLY OUTCOMES FOR THE FIRST PATIENTS WITHIN A 2-ARM
RANDOMIZED AND PARALLEL SLING-VERSUS-SPHINCTER FEASIBILITY
PROTOCOL
Antoine Kass-Iliyya *, Ishaan Chaudhury, Rizwan Hamid,
Daniella E. Andrich, Tamsin J. Greenwell, Julian R. Shah,
Jeremy L. Ockrim. University College London Hospitals, London, UK.
Introduction: Surgical options for men with stress urinary incontinence
(SUI) after radical prostatectomy are male sling or artiﬁcial urinary
sphincter (AUS). No randomized controlled trials are available to compare
these interventions. The Sling-versus-Sphincter (SVS) feasibility protocol
was designed to assess potential for a randomized multicenter study.
Methods: All post prostatectomy SUI patients referred from Feb-Oct 2013
were assessed for eligibility. Objective assessment included 24h pad
weight and urodynamics. Subjective assessment was based on self-re-
ported questionnaires (ICIQMLUTS, EQ5D, PGI-I). Severe incontinence was
considered pad weight >400mls. Patients were treated with the
AMSAdVance sling or AMS800 AUS.
